Phreesia Faces Class Action Lawsuit Risk
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Class Action Notification: The Portnoy Law Firm advises Phreesia investors of a class action for those who purchased securities between May 8, 2025, and March 30, 2026, requiring lead plaintiff motions by July 13, 2026, indicating significant legal risks that may undermine shareholder confidence.
- Revenue Outlook Downgrade: On March 30, 2026, Phreesia lowered its fiscal year 2027 revenue outlook from $545 million to $559 million down to a range of $510 million to $520 million, reflecting reduced visibility into future spending commitments, which could weaken investor confidence in the company's growth prospects.
- Severe Market Reaction: Following the revenue outlook downgrade, Phreesia's stock price plummeted from $11.41 to $8.38 per share, a decline of approximately 27%, highlighting market concerns regarding the company's financial health and potentially impacting its ability to raise capital and maintain market position.
- Decreased Client Spending: The company disclosed that Network Solutions clients were committing lower spending levels for the second half of fiscal year 2027 than anticipated, along with increased variability in revenue forecasting, indicating greater uncertainty in the competitive landscape that could affect its long-term growth strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHR
Wall Street analysts forecast PHR stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.920
Low
24.00
Averages
29.09
High
35.00
Current: 8.920
Low
24.00
Averages
29.09
High
35.00
About PHR
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Phreesia Shareholders Alert: Potential Class Action Lawsuit
- Lawsuit Notification: The Gross Law Firm has issued a notice to shareholders of Phreesia, Inc. (NYSE:PHR), encouraging those who purchased shares during the class period from May 8, 2025, to March 30, 2026, to contact the firm regarding potential lead plaintiff appointment to participate in a class action lawsuit for recovery.
- False Statements Allegations: The complaint alleges that Phreesia provided overly positive statements to investors while concealing adverse facts, particularly regarding weakened pharmaceutical marketing commitments in its Network Solutions segment, leading to a misunderstanding of the company's true condition.
- Revenue Guidance Cut: On March 30, 2026, Phreesia announced a significant reduction in revenue growth projections for fiscal year 2027, attributing the shortfall to macroeconomic factors and diminished visibility in key revenue streams, indicating a troubling trend for the company.
- Stock Price Decline: Following the announcement of reduced revenue guidance, Phreesia's stock price plummeted from $11.41 per share on March 30, 2025, to $8.38 per share on March 31, 2026, marking a decline of approximately 27%, which reflects the market's pessimism regarding the company's future prospects.
See More
Phreesia Faces Class Action Lawsuit Risk
- Class Action Notification: The Portnoy Law Firm advises Phreesia investors of a class action for those who purchased securities between May 8, 2025, and March 30, 2026, requiring lead plaintiff motions by July 13, 2026, indicating significant legal risks that may undermine shareholder confidence.
- Revenue Outlook Downgrade: On March 30, 2026, Phreesia lowered its fiscal year 2027 revenue outlook from $545 million to $559 million down to a range of $510 million to $520 million, reflecting reduced visibility into future spending commitments, which could weaken investor confidence in the company's growth prospects.
- Severe Market Reaction: Following the revenue outlook downgrade, Phreesia's stock price plummeted from $11.41 to $8.38 per share, a decline of approximately 27%, highlighting market concerns regarding the company's financial health and potentially impacting its ability to raise capital and maintain market position.
- Decreased Client Spending: The company disclosed that Network Solutions clients were committing lower spending levels for the second half of fiscal year 2027 than anticipated, along with increased variability in revenue forecasting, indicating greater uncertainty in the competitive landscape that could affect its long-term growth strategy.
See More
Reminder for Phreesia Stock Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Phreesia (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026, to apply as lead plaintiffs by July 13, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Phreesia made false or misleading statements during the class period, concealing adverse facts regarding slowing demand and reduced visibility in key revenue streams, which resulted in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong track record and expertise in this field.
- Investor Guidance: Investors are advised to carefully select legal counsel, with Rosen Law Firm recommending attorneys with proven success in leadership roles to ensure optimal representation and support in the class action.
See More
Phreesia Faces Class Action Lawsuit; Investors Encouraged to Claim Losses
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Phreesia in the U.S. District Court for Delaware on behalf of investors who purchased shares between May 8, 2025, and March 30, 2026, reflecting significant dissatisfaction with the company's financial transparency.
- Allegation Details: The complaint alleges that the company and its executives violated federal securities laws by failing to disclose the true state of slowing demand and weakened pharmaceutical marketing commitments in its Network Solutions segment, leading to a loss of investor confidence.
- Revenue Guidance Cut: On March 30, 2026, Phreesia revised its fiscal year 2027 revenue guidance down to $510 million to $520 million, a reduction of $35 million to $49 million from the previous range of $545 million to $559 million, indicating a decline in market demand.
- Stock Price Volatility: Following the revenue guidance cut, Phreesia's stock plummeted by 21% to 28%, demonstrating extreme investor concern regarding the company's future prospects, which may prompt more investors to seek legal recourse.
See More
Multiple Companies Face Class Action Lawsuits
- Phreesia Lawsuit: Phreesia Inc. faces a class action for allegedly misleading investors about its long-term growth outlook during the period from May 8, 2025, to March 30, 2026, putting its 2027 revenue target at risk, with a lead plaintiff deadline of July 13, 2026.
- Sportradar Allegations: Sportradar Group AG is accused of collaborating with black-market gambling operators and failing to disclose deficiencies in its compliance processes during the class period from November 7, 2024, to April 21, 2026, with a lead plaintiff deadline of July 17, 2026.
- Commvault Issues: Commvault Systems Inc. is facing a lawsuit for not accurately assessing the impact of sales types on its annual recurring revenue growth from April 29, 2025, to January 26, 2026, requiring lead plaintiff motions by July 17, 2026.
- Veritone Financial Misconduct: Veritone, Inc. is under scrutiny for misrecording revenue and costs, necessitating a restatement of financial statements during the class period from October 14, 2025, to April 14, 2026, with a lead plaintiff deadline of July 20, 2026.
See More
Commvault Systems Under Shareholder Investigation for Alleged Misconduct
- Shareholder Investigation Initiated: Grabar Law Office is investigating Commvault Systems, Inc. (NASDAQ: CVLT) for potential breaches of fiduciary duties by its executives, allowing shareholders who purchased shares before April 29, 2025, to seek corporate reforms and fund recovery.
- Allegations of False Statements: A recently filed securities fraud class action alleges that Commvault misled investors through its executives' materially false and misleading statements regarding the true state of its projected ARR growth for fiscal year 2026, leading to investor misconceptions about the company's prospects.
- Negative Market Reaction: The failure to accurately reflect crucial variables in the ARR growth environment has resulted in a significant overstatement of Commvault's financial strength and growth prospects, with investors experiencing multiple financial guidance downgrades between 2024 and 2025.
- Potential Legal Consequences: Should the investigation confirm executive misconduct, the company may face legal liabilities and financial losses, adversely affecting its market reputation and future financing capabilities.
See More
Phreesia Shareholders Alert: Potential Class Action Lawsuit
- Lawsuit Notification: The Gross Law Firm has issued a notice to shareholders of Phreesia, Inc. (NYSE:PHR), encouraging those who purchased shares during the class period from May 8, 2025, to March 30, 2026, to contact the firm regarding potential lead plaintiff appointment to participate in a class action lawsuit for recovery.
- False Statements Allegations: The complaint alleges that Phreesia provided overly positive statements to investors while concealing adverse facts, particularly regarding weakened pharmaceutical marketing commitments in its Network Solutions segment, leading to a misunderstanding of the company's true condition.
- Revenue Guidance Cut: On March 30, 2026, Phreesia announced a significant reduction in revenue growth projections for fiscal year 2027, attributing the shortfall to macroeconomic factors and diminished visibility in key revenue streams, indicating a troubling trend for the company.
- Stock Price Decline: Following the announcement of reduced revenue guidance, Phreesia's stock price plummeted from $11.41 per share on March 30, 2025, to $8.38 per share on March 31, 2026, marking a decline of approximately 27%, which reflects the market's pessimism regarding the company's future prospects.
See More
Phreesia Faces Class Action Lawsuit Risk
- Class Action Notification: The Portnoy Law Firm advises Phreesia investors of a class action for those who purchased securities between May 8, 2025, and March 30, 2026, requiring lead plaintiff motions by July 13, 2026, indicating significant legal risks that may undermine shareholder confidence.
- Revenue Outlook Downgrade: On March 30, 2026, Phreesia lowered its fiscal year 2027 revenue outlook from $545 million to $559 million down to a range of $510 million to $520 million, reflecting reduced visibility into future spending commitments, which could weaken investor confidence in the company's growth prospects.
- Severe Market Reaction: Following the revenue outlook downgrade, Phreesia's stock price plummeted from $11.41 to $8.38 per share, a decline of approximately 27%, highlighting market concerns regarding the company's financial health and potentially impacting its ability to raise capital and maintain market position.
- Decreased Client Spending: The company disclosed that Network Solutions clients were committing lower spending levels for the second half of fiscal year 2027 than anticipated, along with increased variability in revenue forecasting, indicating greater uncertainty in the competitive landscape that could affect its long-term growth strategy.
See More
Reminder for Phreesia Stock Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Phreesia (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026, to apply as lead plaintiffs by July 13, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Phreesia made false or misleading statements during the class period, concealing adverse facts regarding slowing demand and reduced visibility in key revenue streams, which resulted in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong track record and expertise in this field.
- Investor Guidance: Investors are advised to carefully select legal counsel, with Rosen Law Firm recommending attorneys with proven success in leadership roles to ensure optimal representation and support in the class action.
See More
Phreesia Faces Class Action Lawsuit; Investors Encouraged to Claim Losses
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Phreesia in the U.S. District Court for Delaware on behalf of investors who purchased shares between May 8, 2025, and March 30, 2026, reflecting significant dissatisfaction with the company's financial transparency.
- Allegation Details: The complaint alleges that the company and its executives violated federal securities laws by failing to disclose the true state of slowing demand and weakened pharmaceutical marketing commitments in its Network Solutions segment, leading to a loss of investor confidence.
- Revenue Guidance Cut: On March 30, 2026, Phreesia revised its fiscal year 2027 revenue guidance down to $510 million to $520 million, a reduction of $35 million to $49 million from the previous range of $545 million to $559 million, indicating a decline in market demand.
- Stock Price Volatility: Following the revenue guidance cut, Phreesia's stock plummeted by 21% to 28%, demonstrating extreme investor concern regarding the company's future prospects, which may prompt more investors to seek legal recourse.
See More
Multiple Companies Face Class Action Lawsuits
- Phreesia Lawsuit: Phreesia Inc. faces a class action for allegedly misleading investors about its long-term growth outlook during the period from May 8, 2025, to March 30, 2026, putting its 2027 revenue target at risk, with a lead plaintiff deadline of July 13, 2026.
- Sportradar Allegations: Sportradar Group AG is accused of collaborating with black-market gambling operators and failing to disclose deficiencies in its compliance processes during the class period from November 7, 2024, to April 21, 2026, with a lead plaintiff deadline of July 17, 2026.
- Commvault Issues: Commvault Systems Inc. is facing a lawsuit for not accurately assessing the impact of sales types on its annual recurring revenue growth from April 29, 2025, to January 26, 2026, requiring lead plaintiff motions by July 17, 2026.
- Veritone Financial Misconduct: Veritone, Inc. is under scrutiny for misrecording revenue and costs, necessitating a restatement of financial statements during the class period from October 14, 2025, to April 14, 2026, with a lead plaintiff deadline of July 20, 2026.
See More
Commvault Systems Under Shareholder Investigation for Alleged Misconduct
- Shareholder Investigation Initiated: Grabar Law Office is investigating Commvault Systems, Inc. (NASDAQ: CVLT) for potential breaches of fiduciary duties by its executives, allowing shareholders who purchased shares before April 29, 2025, to seek corporate reforms and fund recovery.
- Allegations of False Statements: A recently filed securities fraud class action alleges that Commvault misled investors through its executives' materially false and misleading statements regarding the true state of its projected ARR growth for fiscal year 2026, leading to investor misconceptions about the company's prospects.
- Negative Market Reaction: The failure to accurately reflect crucial variables in the ARR growth environment has resulted in a significant overstatement of Commvault's financial strength and growth prospects, with investors experiencing multiple financial guidance downgrades between 2024 and 2025.
- Potential Legal Consequences: Should the investigation confirm executive misconduct, the company may face legal liabilities and financial losses, adversely affecting its market reputation and future financing capabilities.
See More
